Skip to content
Mianserin
Mianserin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2A. In addition, it is known to target 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 6, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 1B, lysophosphatidic acid receptor 1, alpha-1D adrenergic receptor, alpha-1A adrenergic receptor, and sodium-dependent noradrenaline transporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
behavior and behavior mechanismsD001520
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
depression—D003863F33.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX03: Mianserin
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863F33.9——12—3
Post-traumatic stress disordersD013313EFO_0001358F43.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMIANSERIN
INNmianserin
Description
Mianserin is a dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere. It has a role as an antidepressant, a histamine agonist, a sedative, an alpha-adrenergic antagonist, an adrenergic uptake inhibitor, a serotonergic antagonist, a H1-receptor antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and a geroprotector.
Classification
Small molecule
Drug classserotonin 5-HT2 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCN2c3ccccc3Cc3ccccc3C2C1
Identifiers
PDB—
CAS-ID24219-97-4
RxCUI—
ChEMBL IDCHEMBL6437
ChEBI ID51137
PubChem CID4184
DrugBankDB06148
UNII ID250PJI13LM (ChemIDplus, GSRS)
Target
Agency Approved
HTR2B
HTR2B
HTR2C
HTR2C
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
3357
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Q6P523
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Alternate
HTR7
HTR7
HTR6
HTR6
ADRA1B
ADRA1B
HTR1B
HTR1B
LPAR1
LPAR1
ADRA1D
ADRA1D
ADRA1A
ADRA1A
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
HTR7
Gene synonyms
NCBI Gene ID
3363
Protein name
5-hydroxytryptamine receptor 7
Protein synonyms
5-HT-7, 5-HT-X, 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled), Serotonin receptor 7
Uniprot ID
P34969
Mouse ortholog
Htr7 (15566)
5-hydroxytryptamine receptor 7 (Q14A50)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,582 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,172 adverse events reported
View more details